Key statistics
On Friday, WAVE Life Sciences Ltd (WVE:NMQ) closed at 16.44, -0.18% below its 52-week high of 16.47, set on Nov 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.70 |
---|---|
High | 16.47 |
Low | 14.55 |
Bid | 16.52 |
Offer | 16.75 |
Previous close | 14.83 |
Average volume | 1.29m |
---|---|
Shares outstanding | 145.60m |
Free float | 122.62m |
P/E (TTM) | -- |
Market cap | 2.39bn USD |
EPS (TTM) | -0.5796 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:15 GMT.
More ▼
- Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
- Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
- Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
- Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
- Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
- Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
- Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
More ▼